Rahel Alemu
Family · Easton, MDNPI 1427506583
Payments from drug & device makers
Across 264 payments — averaging $17.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$922
- Teva Pharmaceuticals USA, Inc.$523
- Harmony Biosciences LLC$386
- Lilly USA, LLC$284
- Biohaven Pharmaceutical Holding Company Ltd.$283
- Biogen$238
- plus $2K from 30 others
What the payments were for
- Food & beverage$4,46697%
- Education$1563%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 87 | $922 |
| Teva Pharmaceuticals USA, Inc. | 20 | $523 |
| Harmony Biosciences LLC | 12 | $386 |
| Lilly USA, LLC | 14 | $284 |
| Biohaven Pharmaceutical Holding Company Ltd. | 24 | $283 |
| Biogen | 12 | $238 |
| Amneal Pharmaceuticals LLC | 5 | $145 |
| Lundbeck LLC | 6 | $138 |
| UCB, Inc. | 6 | $137 |
| Jazz Pharmaceuticals Inc. | 6 | $134 |
| Sumitomo Pharma America, Inc. | 10 | $114 |
| Eisai Inc. | 4 | $102 |
| Neurocrine Biosciences, Inc. | 4 | $96 |
| Pfizer | 5 | $95 |
| Bristol Myers Squibb | 5 | $85 |
| EMD Serono, Inc. | 4 | $80 |
| Amgen | 3 | $78 |
| Argenx US, Inc. | 3 | $76 |
| Axsome Therapeutics, Inc. | 3 | $75 |
| Neurelis, Inc. | 4 | $73 |
| Otsuka America Pharmaceutical, Inc. | 3 | $65 |
| Acadia Pharmaceuticals Inc | 3 | $55 |
| Genentech USA, Inc. | 3 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $51 |
| ANI Pharmaceuticals, Inc. | 2 | $49 |
| Kyowa Kirin, Inc. | 3 | $46 |
| Life Molecular Imaging Ltd | 2 | $42 |
| Mallinckrodt Hospital Products Inc. | 1 | $31 |
| GE HealthCare | 1 | $31 |
| Alnylam Pharmaceuticals Inc. | 1 | $25 |
| Tanabe Pharma America, Inc. | 1 | $24 |
| 3b Medical, Inc. | 1 | $21 |
| Sunovion Pharmaceuticals Inc. | 1 | $20 |
| Catalyst Pharmaceuticals, Inc. | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $11 |
How this compares
$4,623 in reported general payments places this provider in the 90th percentile of 2,843 family providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TecfideraDimethyl Fumarate | 17 | $247,406 |
| IngrezzaValbenazine Tosylate | 25 | $191,959 |
| Nurtec OdtRimegepant Sulfate | 29 | $52,504 |
| UbrelvyUbrogepant | 22 | $23,614 |
| Emgality PenGalcanezumab-Gnlm | 30 | $21,729 |
| Aimovig AutoinjectorErenumab-Aooe | 16 | $11,114 |
| Lacosamide | 41 | $5,681 |
| Carbamazepine ErCarbamazepine | 31 | $5,627 |
| Levetiracetam | 229 | $5,491 |
| Divalproex Sodium | 23 | $5,281 |
| Divalproex Sodium ErDivalproex Sodium | 60 | $5,051 |
| Memantine Hcl | 133 | $3,414 |
| Gabapentin | 189 | $3,005 |
| Carbamazepine | 41 | $2,981 |
| Pregabalin | 72 | $2,308 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenTecfidera | $238 | $247,40617 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $96 | $191,95925 claims |
| PfizerNurtec Odt | $95 | $52,50429 claims |
| AbbVieUbrelvy | $922 | $23,61422 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $145 | $21012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,843 family providers in Maryland.
Other family in Easton
- Ariana ChaoLutherville$727K
- Erika HoffmanPotomac$226K
- Caroline MansySalisbury$106K
- Hazel Jones-ParkerBaltimore$96K
- Brittany WilsonBaltimore$88K
- Meredith SagalHunt Valley$82K
- Sharon Dudley-BrownBel Air$67K
- Joy MaulikSalisbury$47K
- Kristin AttiogbeChevy Chase$42K
- Sametta SanyaoluFulton$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.